| Chad Ross, PT | |
|
2203 W Dimond Blvd Ste 100a, Anchorage, AK 99515-4517 | |
| (907) 349-5801 | |
| (907) 349-5802 |
| Full Name | Chad Ross |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 28 Years |
| Location | 2203 W Dimond Blvd Ste 100a, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518023555 | NPI | - | NPPES |
| PT1342 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 1342 (Alaska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| United Physical Therapy Inc | 1355231853 | 24 |
News Archive
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
Pulmonary fibrosis is a scarring or thickening of the lungs that causes shortness of breath, a dry cough, fatigue, chest discomfort, weight loss, a decrease in the ability of the lungs to transmit oxygen to the blood stream, and, eventually, heart failure.
On Monday, Dec. 13, the Canadian Medical Association (CMA) will launch a national initiative related to the future of Canada's health care system.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company's New Drug Application (NDA) for Fampridine-SR on October 14, 2009.
Is your thyroid making you fat? Around 27 million Americans have thyroid disease — and almost half don't know it. Thyroid disease arises when the hormone-producing gland at the base of your throat goes out of whack, triggering weight fluctuation, tiredness, and emotional ups and downs, among other symptoms.
› Verified 4 days ago
| Provider Name | United Physical Therapy Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1609888130 PECOS PAC ID: 1355231853 Enrollment ID: O20040318000366 |
News Archive
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
Pulmonary fibrosis is a scarring or thickening of the lungs that causes shortness of breath, a dry cough, fatigue, chest discomfort, weight loss, a decrease in the ability of the lungs to transmit oxygen to the blood stream, and, eventually, heart failure.
On Monday, Dec. 13, the Canadian Medical Association (CMA) will launch a national initiative related to the future of Canada's health care system.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company's New Drug Application (NDA) for Fampridine-SR on October 14, 2009.
Is your thyroid making you fat? Around 27 million Americans have thyroid disease — and almost half don't know it. Thyroid disease arises when the hormone-producing gland at the base of your throat goes out of whack, triggering weight fluctuation, tiredness, and emotional ups and downs, among other symptoms.
› Verified 4 days ago
| Provider Name | Advanced Physical Therapy Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1437214459 PECOS PAC ID: 0941228548 Enrollment ID: O20051102000678 |
News Archive
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
Pulmonary fibrosis is a scarring or thickening of the lungs that causes shortness of breath, a dry cough, fatigue, chest discomfort, weight loss, a decrease in the ability of the lungs to transmit oxygen to the blood stream, and, eventually, heart failure.
On Monday, Dec. 13, the Canadian Medical Association (CMA) will launch a national initiative related to the future of Canada's health care system.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company's New Drug Application (NDA) for Fampridine-SR on October 14, 2009.
Is your thyroid making you fat? Around 27 million Americans have thyroid disease — and almost half don't know it. Thyroid disease arises when the hormone-producing gland at the base of your throat goes out of whack, triggering weight fluctuation, tiredness, and emotional ups and downs, among other symptoms.
› Verified 4 days ago
| Provider Name | Perception Physical Therapy Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1326697764 PECOS PAC ID: 5395174643 Enrollment ID: O20200407003477 |
News Archive
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
Pulmonary fibrosis is a scarring or thickening of the lungs that causes shortness of breath, a dry cough, fatigue, chest discomfort, weight loss, a decrease in the ability of the lungs to transmit oxygen to the blood stream, and, eventually, heart failure.
On Monday, Dec. 13, the Canadian Medical Association (CMA) will launch a national initiative related to the future of Canada's health care system.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company's New Drug Application (NDA) for Fampridine-SR on October 14, 2009.
Is your thyroid making you fat? Around 27 million Americans have thyroid disease — and almost half don't know it. Thyroid disease arises when the hormone-producing gland at the base of your throat goes out of whack, triggering weight fluctuation, tiredness, and emotional ups and downs, among other symptoms.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chad Ross, PT 2203 W Dimond Blvd Ste 100a, Anchorage, AK 99515-4517 Ph: (907) 349-5801 | Chad Ross, PT 2203 W Dimond Blvd Ste 100a, Anchorage, AK 99515-4517 Ph: (907) 349-5801 |
News Archive
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
Pulmonary fibrosis is a scarring or thickening of the lungs that causes shortness of breath, a dry cough, fatigue, chest discomfort, weight loss, a decrease in the ability of the lungs to transmit oxygen to the blood stream, and, eventually, heart failure.
On Monday, Dec. 13, the Canadian Medical Association (CMA) will launch a national initiative related to the future of Canada's health care system.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company's New Drug Application (NDA) for Fampridine-SR on October 14, 2009.
Is your thyroid making you fat? Around 27 million Americans have thyroid disease — and almost half don't know it. Thyroid disease arises when the hormone-producing gland at the base of your throat goes out of whack, triggering weight fluctuation, tiredness, and emotional ups and downs, among other symptoms.
› Verified 4 days ago
Katrina F Johnson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-563-2662 | |
Jessie Lief, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4031 Winchester Loop, Anchorage, AK 99507 Phone: 907-244-8048 | |
Zoe Anneliese Morris Nelson, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1917 Abbott Rd Ste 200, Anchorage, AK 99507 Phone: 907-279-4266 | |
Normajean Farr, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2221 E Northern Lights Blvd, Suite 106, Anchorage, AK 99508 Phone: 907-677-5605 | |
Mary Beth Nearing, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 602 W 42nd Ave, Anchorage, AK 99503 Phone: 907-360-9448 Fax: 907-346-1470 | |
Kids Are People Too Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6311 Debarr Rd, Suite J, Anchorage, AK 99504 Phone: 907-830-3592 Fax: 907-338-4691 | |
Ms. Catherine A Coward, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 9500 Independence Dr, Ste 900, Anchorage, AK 99507 Phone: 907-522-1341 Fax: 907-522-1343 |